TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive Bristol Stock Drops Amid New Setbacks, Deepening Firm’s Decline In Oncology April 5, 2002